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Purpose: We investigated the value of an interferon-γ release assay (IGRA) for the 
diagnosis of active pulmonary tuberculosis (PTB) among sputum smear negative 
PTB suspects in an environment with intermediate burden of PTB and high Bacillus 
Calmette-Guérin (BCG) vaccination rate. Materials and Methods: We retrospec-
tively reviewed IGRA, medical records, chest PA and CT scan of PTB suspects seen 
at Gangnam Severance Hospital, Seoul, Korea from Oct. 2007 to Apr. 2013. “Ac-
tive PTB” was diagnosed when 1) M. tuberculosis culture positive, 2) confirmation 
by pathologic examination; or 3) clinical findings compatible with TB. Results: Of 
224 sputum smear negative PTB suspects, 94 were confirmed as having active PTB. 
There were no statistically significant differences in the diagnostic yield of IGRA 
between immunocompromised and immunocompetent sputum smear negative PTB 
suspects. IGRA did show superior sensitivity [81.9%, 95% confidence interval (CI); 
74.13-89.70%] in the diagnosis of sputum smear negative PTB when compared 
with chest high-resolution computed tomography (HRCT), tuberculin skin test 
(TST), and chest X-ray (p<0.001). Also, IGRA showed highest negative predictive 
value (82.7%, 95% CI; 75.16-90.15%) when compared with HRCT, TST and chest 
X-ray (p=0.023). However, combining the results of IGRA with those of HRCT, 
TST, or both did not increase any diagnostic parameters. Conclusion: Failure to in-
crease diagnostic yields by combination with other diagnostic modalities suggests 
that additional enforcement with IGRA may be insufficient to exclude other diagno-
ses in sputum smear negative PTB suspects and to screen active PTB in an environ-
ment with intermediate TB prevalence and a high BCG vaccination rate.
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INTRODUCTION
 
Tuberculosis (TB) is a major worldwide health problem with a global estimate of 
9.4 million incidence in 2010 (range; 8.9×106-9.9×106). Although there has been a 
slow reduction in the incidence rate per capita, the absolute number of TB cases 
continues to increase from year to year due to population growth. Approximately 
1.7 million people died of TB in 2009, encompassing human immunodeficiency vi-
rus (HIV)-negative and HIV-positive cases, which estimates 26 death per 100000 
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tive disease. Because of the smaller mycobacterium burden 
present in smear negative disease, typical radiographic pat-
terns of TB are sometimes difficult to detect in patients with 
sputum smear negative disease.9 The interferon-γ release as-
say (IGRA) test, an in vitro immunodiagnostic test, mea-
sures the effect of T cell mediated interferon (IFN)-γ re-
sponse to M. tuberculosis-specific antigens. Three promising 
antigens used in this assay are absent in the BCG and NTM 
strains,10,11 making IGRA highly specific for the diagnosis of 
active and latent TB in BCG-vaccinated individuals. How-
ever, both IGRA and TST are limited by their inability to 
distinguish between active disease and latent infection with 
M. tuberculosis.12,13 
In this study, we evaluated the diagnostic utility of IGRA, 
comparing clinical findings, chest X-ray, chest HRCT, and 
TST for the diagnosis of active PTB among smear negative 
PTB suspects, in a region of the world where the incidence 
and prevalence of active PTB is intermediate and BCG vac-
cination is mandatory. We also analyzed whether IGRA fa-
cilitates diagnosis of active PTB when combined with other 
diagnostic modalities in sputum smear negative PTB suspect.
MATERIALS AND METHODS
　　　
Study setting and subjects
Clinical records, TST, HRCT findings and IGRA results 
were retrospectively gathered from of all patients with sus-
pected PTB seen from October 2007 to April 2013 at 
Gangnam Severance Hospital (the referral center), Seoul, 
Korea. Patients with IGRA results that were 1) indetermi-
nate or 2) performed more than 14 days into a course of TB 
treatment were excluded from this study. Patients younger 
than 18 years of age, without more than 2 separate sputum 
acid fast bacilli (AFB) smear examinations, and with an in-
conclusive diagnosis owing to the loss of follow-up were 
also excluded. The recorded clinical information on includ-
ed patients included age, gender, previous TB history and 
co-morbidity. The protocol for this study was approved by 
the ethical review committee of Gangnam Severance Hos-
pital (IRB No. 3-2010-0234). This study was exempted 
from the requirement to obtain informed consent.
Diagnostic definition 
A case with “suspected PTB” was defined as an individual 
with clinical or radiographic evidence consistent with ac-
tive PTB; subacute or chronic respiratory symptoms more 
population.1,2 During 2010, 36305 new TB patients were 
identified (74.3 cases per 100000), with 28176 (57.6 cases 
per 100000; 77.6% of TB cases) new pulmonary TB cases in 
the Republic of Korea in 2010 alone.3 According to a 2010 
World Health Organization report (50-99/100000 per year),1 
the incidence of active TB in Korea, is intermediate, and Ba-
cillus Calmette-Guérin (BCG) vaccination is mandatory.
Among the 4.6 million new and relapsed cases of pulmo-
nary tuberculosis (PTB) reported worldwide in 2009, 2.0 
million new cases (34.5%) were sputum smear negative 
PTB. In 2010, the Korean National Tuberculosis Associa-
tion reported that 10776 cases among 28176 active PTB 
cases were sputum smear positive (38.2%).3 Delayed treat-
ment often happens due to the difficulties of diagnosis, 
therefore, sputum smear negative PTB is an important cause 
of community transmission even though it is less infectious 
than sputum smear positive PTB,4 frequently resulting in ir-
reversible lung damage. In an intermediate TB burden 
country such as the Republic of Korea where most of neo-
nates administered BCG vaccination within 4-weeks of age 
on the basis of national policy, the diagnosis of sputum 
smear negative PTB is difficult. Many patients harbor 
healed lesions from previous TB, compromising sputum 
smear results from non-tuberculosis mycobacterium 
(NTM) disease due to structural lung lesion, and false posi-
tive tuberculin skin test (TST) results due to mandatory 
BCG vaccination.
Alternative tests must be used to compensate for the diag-
nostic difficulties encountered in smear negative PTB spu-
tum studies. Chest X-rays are often used in PTB screening 
and have the advantages of being simple and inexpensive. 
But in smear negative PTB, many cases show atypical or 
non-specific patterns5 and have high false positive rates due 
to previous PTB infection in intermediate or high TB burden 
countries. Although TST has been shown to be cost-effective 
and is well known for diagnostic accuracy for smear negative 
PTB and latent TB infections, its sensitivity is also influenced 
by nutritional and immune status.6 Moreover, cross-reactivity 
with NTM and BCG vaccination adversely affects its diag-
nostic value for sputum smear negative PTB. Because the 
sputum M. tuberculosis-polymerase chain reaction assay 
provides prompt results and is non-cross-reactive to NTM 
strains, it has been used as an adjunct diagnostic method for 
the diagnosis of smear negative PTB, but it has low sensi-
tivity in smear negative cases.7,8 High-resolution computed 
tomography (HRCT) offers not only the extent and distribu-
tion of PTB, but also helps to distinguish active from inac-
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10 mm or greater in size occurring 48-72 h after injection. 
The IGRA test was performed with QFT-IT in the Immunol-
ogy Laboratory at Severance Hospital according to the rec-
ommendations of the manufacturer (Cellestis Ltd; Carne-
gie, Australia), as previously described.14
Statistics
Data were analyzed with SPSS version 20.0 statistical soft-
ware (SPSS Inc., Chicago, IL, USA). Univariate comparisons 
between active PTB and non-TB patients were performed us-
ing Fisher’s exact tests for categorical variables and Mann-
Whitney tests for continuous variables where appropriate. 
Sensitivity, specificity, positive predictive value (PPV) and 
negative predictive value (NPV) for the diagnosis of active 
PTB were calculated for each diagnostic modality and com-
pared with McNemar’s test. All tests of significance were two 
sided; p<0.05 was considered statistically significant and 
95% confidence intervals (95% CIs) were calculated. 
RESULTS
 
Demographic characteristics
From 2007 to 2013, a total of 368 patients with suspected 
active PTB visited our institute. Of these, 41 cases were ex-
cluded due to young ages (n=19) and insufficient sputum 
studies (n=22). Of the remaining 327 cases with suspected 
PTB, 35 cases were further excluded due to indeterminate 
IGRA results (n=21), inconclusive diagnosis (n=1), or an 
IGRA test more than 14 days after anti-TB treatment (n=13) 
(Fig. 1). The final diagnoses of patients with indeterminate 
than 3 weeks and infiltration of chest PA which is suspi-
cious for PTB. “Active PTB” was diagnosed when 1) M. 
tuberculosis was cultured, 2) a caseating granuloma was 
found in the lung tissue by transthoracic needle biopsy and 
showed appropriate response to treatment; or 3) clinical 
findings were compatible with TB, no clinical improve-
ment was seen with empirical antibiotics, and treatment 
with anti-TB medication resulted in clinical and radiological 
improvement. A final diagnosis of ‘Non-TB’ was accepted 
when the one who was suspected to have PTB by the above 
mentioned criteria and finally reached an alternative diag-
nosis. An “immunocompromised condition” was defined as 
described previously.14 Briefly, the patients 1) with DM, 2) 
who underwent chemotherapy for an underlying malignan-
cy at the time of TST and QuantiFERON-TB Gold In-Tube 
(QFT-IT), 3) received either a solid organ transplant or bone 
marrow transplant, 4) on renal replacement therapy, 5) with 
advanced liver cirrhosis (Child-Pugh class C), 6) seroposi-
tive for human immunodeficiency virus, and 7) adminis-
tered systemic corticosteroids (at least 15 mg of prednisone 
per day for more than one month or combination therapy 
with low dose corticosteroids and other immunosuppres-
sants including azathioprine, mycophenolate, methotrexate, 
cyclosporine, or cyclophosphamide) were defined as im-
munocompromized.
TST and IGRA
TST was performed by injecting a 2-TU dose of purified pro-
tein derivative RT23 (Statens Serum Institut, Copenhagen, 
Denmark) intradermally into the forearm using the Mantoux 
test. The criterion for a positive TST result was an induration 
Fig. 1. Study flow diagram. *Confirmed=positive culture results+clinical diagnosis (with negative culture results). †Confirmed=negative culture results without 
clinical evidence of PTB. TB, tuberculosis; n, number; QFT-IT, QuantiFERON-TB Gold In-Tube; PTB, pulmonary tuberculosis; AFB, acid fast bacilli.
Confirmed*
Active PTB, n=94
Confirmed† 
Non-PTB, n=130
Confirmed*
Active PTB, n=64
Confirmed† 
Non-PTB, n=4
Exclusion criteria
1. Younger than 18 years of age, n=19
2. Without more than 2 separate AFB smear examination, 
    n=22
Excluded during study (n=35)
1. Inconclusive diagnosis owing to loss of follow-up, n=1
2. Indeterminate QFT-IT results, n=21
3. QFT-IT performed more than 14 days into a course of 
    PTB treatment, n=13
Active PTB suspects, n=368
(1/9/07-20/04/13)
QFT-IT, n=327
Sputum smear negative, active 
PTB suspects, n=224 AFB smear positive, n=68
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Sputum, chest pain, and weight loss were meaningful 
clinical characteristics in sputum smear negative PTB 
suspects
Previous studies showed that symptoms such as cough, spu-
tum, fever, hemoptysis, chest pain, and/or weigh loss are 
meaningful clinical parameters for the diagnosis of sputum 
smear negative PTB.8,15,16 Therefore, respiratory symptoms 
such as cough, sputum, hemoptysis, and chest pain, as well 
as non-respiratory symptoms such as fever and weight loss 
were investigated through in-person interviews by asking 
whether symptoms were present or not. If the PTB suspects 
complained of multiple symptoms, one main complaint from 
the above list of symptoms was selected by the physician. 
Among the symptoms of the PTB suspects, the presence of 
productive sputum, chest pain and weight loss were signifi-
cantly different between active PTB and non-TB patients, 
which is comparable to previous studies.8,15,16 Twelve (5.4%) 
out of 224 suspects complained of weight loss as a main 
symptom; this complaint was more frequent in active PTB 
patients among sputum smear negative TB suspects (p= 
0.017, McNemar’s test) (Table 2).
IGRA showed the highest sensitivity and NPV
To investigate the diagnostic usefulness of IGRA for the di-
agnosis of active PTB from smear negative PTB suspects, 
we compared the sensitivity, specificity, PPV, and NPV of 
IGRA with chest X-ray, TST, and chest HRCT (Table 3). 
IGRA results are as follows: 4 cases (15.4%) were con-
firmed to be PTB and the other 17 non-TB. The diagnosis of 
17 non-TB indeterminate cases were as follows; pneumonia 
7, malignancy 2, diffuse interstitial lung disease 1, NTM 1, 
TB sequelae 1, other 5. 9 out of 21 indeterminate cases were 
immunocompromised and 7 cases had history of PTB. 
Among the 292 cases, 68 cases showed sputum AFB smear 
positivity (Fig. 1); 64 cases (94.1%) were confirmed PTB by 
either mycobacterial culture study (58 cases), biopsy and 
pathologic confirmation (2 cases), or clinical diagnosis (4 
cases). On the other hands, 4 cases were confirmed as non-
tuberculous mycobacterial infection. The remaining 224 
cases were defined as sputum smear negative PTB, and their 
characteristics are summarized in Table 1. During the follow 
up, 94 cases (42.0%) were diagnosed as active PTB; 60 
(63.8%) resulted in positive M. tuberculosis culture, 9 
(9.6%) cases were confirmed by biopsy, and 25 (25.5%) 
were diagnosed clinically. The risk factors for the immuno-
compromised were found in 45 patients, including hemato-
logic malignancy and solid cancer in those undergoing che-
motherapy (Supplementary Table 1, only online). The 
sensitivity and specificity of IGRA in immunocompromised 
patients were 75.0% and 69.0%, whereas those in immuno-
competent patients were 83.3% and 60.4%, respectively, in-
dicating that the immune status of PTB suspects does not in-
fluence IGRA results (p=0.179, χ2-test) (Supplementary 
Table 2, only online).
Table 1. Demographic and Clinical Characteristics of Patients with Suspected Active PTB among the Sputum AFB Smear 
Negative Patients
Characteristic TB (n=94) Non-TB (n=130)
Age, yrs, mean±SD 46.5±20.43 56.6±18.25
Male, n (%)   60 (63.8) 73 (56.6)
Old pulmonary history, n (%) 18 (9.1) 36 (27.7)
Final diagnosis, n (%)
    Active pulmonary TB
        Culture confirmed   60 (63.8)
        Biopsy confirmed   9 (9.6)
        Clinical diagnosed*   25 (25.5)
    Other than TB
        Pneumonia 70 (53.8)
        Lung cancer 8 (6.2)
        Interstitial lung disease 6 (4.6)
        Nontuberculous mycobacterium 17 (13.1) 
        Aspergilloma 1 (0.8)
        Sequelae of previous TB infection 19 (14.6)
        Pulmonary edema 6 (4.6)
        Others 3 (2.3)
TB, tuberculosis; SD, standard deviation; n, number; PTB, pulmonary tuberculosis; AFB, acid fast bacilli.
*Clinical findings being compatible with TB, no clinical improvement with empirical antibiotics, and clinico-radiological improvement with treatment with 
anti-TB medication.
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with those of TST and/or HRCT would increase the diag-
nostic yields of active PTB from sputum smear negative 
PTB suspects. As shown in Table 4, the combination of 
IGRA and HRCT did not increase diagnostic sensitivity, but 
rather decreased the specificity from 62.3% to 46.7% (p< 
0.001, McNemar’s test) (Table 4). Combining the results of 
IGRA and TST did not increase sensitivity, but the specifici-
ty decreased from 62.3% to 36.4% (p<0.001, McNemar’s 
test) (Table 4).When the results of IGRA were combined 
with TST and HRCT, the specificity decreased from 62.3% 
to 27.0% (p<0.001, McNemar’s test) (Table 4). When com-
bined with the results of HRCT, TST, or both, PPV and NPV 
of IGRA were not statistically significantly effective. Taken 
together, combining the results of IGRA with HRCT and/or 
TST did not increase the diagnostic yields of active PTB 
from sputum smear negative PTB suspects. 
DISCUSSION
Fast and accurate diagnosis of sputum smear negative PTB 
is often challenging and delayed diagnosis is not uncom-
mon in daily medical practices. Although IGRA and TST 
The sensitivity of the TST, taking a 10-mm induration as 
the cutoff, was 58.1% (95% CI; 45.78-70.35%), and its 
specificity was 63.6% (95% CI; 49.42-77.85%). The sensi-
tivity of HRCT was 66.7% (95% CI; 56.76-76.57%), and 
the specificity was 71.0% (95% CI; 62.43-79.62%). Chest 
X-ray showed sensitivity of 31.9% (95% CI; 22.49-41.34%) 
and specificity of 73.1% (95% CI; 65.45-80.70%). IGRA 
was the most sensitive modality among the tests deployed in 
this study at 81.9% (95% CI; 74.13-89.70%, p<0.001, 
McNemar’s test) with a specificity of 62.3% (95% CI, 53.98- 
70.64%), which is comparable to other tests (p=0.271, 
McNemar’s test). Although there were no differences in 
PPV among IGRA, HRCT, and TST, IGRA showed higher 
NPV (82.7%, 95% CI; 75.16-90.15%, p<0.001, McNemar’s 
test) than TST (51.9%, 95% CI; 38.52-65.18%), chest X-ray 
(59.8%, 95% CI; 52.13-67.37%), and HRCT (75.4%, 95% 
CI; 63.83-80.93%). Thus, IGRA showed the modest sensi-
tivity and NPV for the diagnosis of active PTB among spu-
tum smear negative TB suspects.
Combinations with TST and/or HRCT did not increase 
the sensitivity and NPV of IGRA
We questioned whether the combination of IGRA results 
Table 2. Symptoms of Sputum Smear Negative TB Suspects
Characteristic TB (n=94)* Non-TB (n=130)† Total (n=224) p value‡
First symptom, n (%) <0.001
    Cough   27 (12.1)   24 (10.7)   51 (22.8) 0.070
    Sputum 14 (6.2)   51 (22.8)   65 (29.0) <0.001
    Fever 12 (5.4)   26 (11.6)   38 (17.0) 0.155
    Hemoptysis   6 (2.7) 12 (5.4) 18 (8.0) 0.439
    Chest pain 22 (9.8) 13 (5.8)   35 (15.6) 0.006
    Weight loss   9 (4.0)   3 (1.3) 12 (5.4) 0.017
TB, tuberculosis; n, numbers; PTB, pulmonary tuberculosis.
The patients, who did not have symptoms, but suspicious for PTB were screened by either annual national health screening program or by medical check-
up at work place and referred to study institute.  
*4 patients had no symptoms.
†1 patient had no symptoms.
‡Calculated with chi-square test.
Table 3. Diagnostic Accuracy in Sputum Smear Negative TB Suspects
Sensitivity (CI)‡ Specificity (CI) PPV (CI) NPV (CI)‡ Accuracy
QFT-IT 81.9 (74.13-89.70) 62.3 (53.98-70.64) 61.1 (52.60-69.62) 82.7 (75.16-90.15) 70.5 (64.57-76.51)
TST* 58.1 (45.78-70.35) 63.6 (49.42-77.85) 69.2 (56.69-81.78) 51.9 (38.52-65.18) 60.4 (51.07-69.69)
HRCT† 66.7 (56.76-76.57) 71.0 (62.43-79.62) 65.2 (55.27-75.07) 75.4 (63.83-80.93) 69.1 (62.57-75.58)
CXR 31.9 (22.49-41.34) 73.1 (65.45-80.70) 46.2 (34.03-58.27) 59.8 (52.13-67.37) 55.8 (49.30-62.31)
CI, confidence interval; QFT-IT, QuantiFERON-TB Gold In-Tube; TST, tuberculin skin test; HRCT, high-resolution chest chest high resolution computer tomog-
raphy; TB, tuberculosis; CXR, chest X-ray.
*106 of 224 cases were examined with this test. 
†194 of 224 cases were examined with this test.
‡p-value: <0.0001 calculated by chi-square test.
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Our IGRA results showed modest sensitivity of 81.9% 
and specificity of 62.3% when compared with previous 
studies in sputum smear negative PTB suspects.10,11,16,20,21 
Similar findings were observed in the analysis of all PTB 
suspects (Supplementary Table 3, only online). Among 134 
non-TB cases [130 cases of sputum smear (-) PTB suspects 
and 4 case of sputum AFB smear (+) that were finally 
proved NTM], 51 (38.1%) showed positive IGRA results; 
25 cases of pneumonia, history of TB 15 and NTM 6, ma-
lignancy 2, interstitial lung disease 2, other 1. This low spec-
ificity of IGRA drew concerns on the diagnostic value of 
IGRA for rapid diagnosis of PTB in patients whose initial 
presentations were suspicious PTB.
 In comparison of the previous reports that had compared 
usefulness of IGRA with individual tests which are current-
ly being deployed for the diagnosis of latent/active TB, this 
study focused on finding out the diagnostic value of IGRA 
when combined with other tests (TST, chest PA, and/or 
HRCT) in a subset of PTB patients who frequently suffer 
difficulties from delayed diagnosis. The environment of this 
study setting is also comparable to the prior reports; inter-
mediate burden of PTB country and 98.8% of neonates are 
vaccinated by BCG. 
However, this study has some limitations because it was 
based on the retrospective observations in a referral hospi-
tal. The clinicians who made the diagnosis of PTB even 
with negative mycobacterial culture results were not blinded 
to the patients’ signs and symptoms, and might have been 
swayed toward the PTB diagnosis. It is difficult to clarify 
the relationship between the exposure time and results of 
IFN-γ. In a time course study on the cytokine gene expres-
sion using M. Tuberculosis infected quinea pig model, ex-
pression of IFN-γ was induced between 3 and 6 weeks of 
infection and gradually decreased.22 The observations in a 
referral hospital might not also be representative of the ex-
periences in primary care.
could not distinguish the disease and latent M. Tuberculosis 
infection, they represent the presence of M. tuberculosis in 
the body of patients, therefore, authors hypothesized that 
combining that of IGRA with those of HRCT and/or TST 
would increase diagnostic yields of sputum negative PTB 
in this study setting.
Several previous studies have evaluated clinical charac-
teristics and scoring systems for the diagnosis of sputum 
smear negative PTB.8,15,16 Samb, et al.8 reported that a 
chronic cough lasting longer than 3 weeks, chest pains last-
ing longer than 15 days, the absence of sputum, and the ab-
sence of dyspnea are independent predictors of active PTB, 
but the PPVs of these clinical predictors were only 50%. 
Lee, et al.16 reported that lack of sputum was a predictor of 
active PTB with similar PPV. Our study demonstrated that 
while sputum showed a negative tendency, it did not reach 
statistical significance between the PTB and non-TB group 
and that weight loss was the only positive predictor of ac-
tive PTB in sputum smear negative PTB suspects.
Kang, et al.17 and Aichelburg, et al.18 reported that the 
sensitivity of IGRA is not different between immunocom-
petent patients and immunocompromised patients. These 
results are compatible to the results of our study, which 
suggested that IGRA results are also not affected by im-
mune status. Based on the Korean Government policy, ev-
ery neonate should be vaccinated BCG once within 4 
weeks of age. The report “2010 Korea National Immuniza-
tion Survey” showed that the BCG vaccination rate of 
South Korea is 98.8%. It had been suggested that BCG vac-
cination may influence the results of TST whereas it does 
not influence those of IGRA. However, studies performed 
in the settings where BCG vaccination is administered once 
at infancy showed that its influence on the results of TST is 
limited.19 This is comparable to our findings which showed 
lower TST positivity, compared IGRA in this country with 
high BCG vaccination rate and intermediate TB burden. 
Table 4. Analysis of Combination of Tests in Sputum Smear Negative PTB Suspects
Sensitivity (CI) Specificity (CI)‡ PPV (CI) NPV (CI) Accuracy
QFT-IT 81.9 (74.13-89.70) 62.3 (53.98-70.64) 61.1 (52.60-69.62) 82.7 (75.16-90.15) 70.5 (64.57-76.51)
QFT-IT+HRCT† 87.4 (80.37-94.34) 46.7 (37.28-56.18) 57.1 (48.73-65.55) 82.0 (72.32-91.62) 65.0 (58.23-71.66)
QFT-IT+TST* 85.5 (76.72-94.25) 36.4 (22.15-50.58) 65.4 (55.07-75.79) 64.0 (45.18-82.82) 65.1 (56.02-74.17)
QFT-IT+HRCT†+  
  TST*
89.3 (81.19-97.39) 27.0 (12.72-41.34) 64.9 (54.28-75.59) 62.5 (38.78-86.22) 64.5 (54.79-74.24)
CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value; QFT-IT, QuantiFERON-TB Gold In-Tube; TST, tuberculin skin test; HRCT, 
high-resolution chest chest high resolution computer tomography; PTB, pulmonary tuberculosis.
*194 of 224 cases were examined with this test. 
†106 of 224 cases were examined with this test.
‡p-value: <0.0001, calculated by chi-square test.
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 In conclusion, despite that IGRA did show superior sensi-
tivity and NPV in the diagnosis of sputum smear negative 
PTB when compared with other diagnostic modalities, com-
bining the results of IGRA with those of HRCT, TST, or 
both did not increase any of the diagnostic parameters. Fail-
ure to increase diagnostic yields by combination with other 
diagnostic modalities suggests that additional enforcement 
with IGRA may be ineffective on diagnose and rule out ac-
tive PTB in sputum smear negative PTB suspects in a situa-
tion with intermediate TB prevalence and high rates of BCG 
vaccination. 
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